top of page

The Lancet Journal - Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2

ibraheem278
Jan 30, 2024
1 min read

Updated: Feb 5, 2024

Published: January 29, 2024 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext

Recent Posts

Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025

Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025

Selective nitric oxide redistribution by phospholipid nanoparticles: A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock

Selective nitric oxide redistribution by phospholipid nanoparticles: A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock

Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals

Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals

Comments

bottom of page